CHEMED CORP

Company Overview

Chemed Corporation is a diversified, acquisition-oriented holding company whose two principal operating segments are VITAS (hospice and palliative care) and Roto-Rooter (plumbing, sewer/drain cleaning, excavation and water-restoration services). The company operates a decentralized model with local operating units running day-to-day operations while corporate directs strategy, capital allocation and legal matters; recent deal activity includes the April 2024 Covenant Care purchase and multiple Roto-Rooter franchise acquisitions. Operations are labor‑intensive (≈15,700 employees at year-end 2024), VITAS is highly dependent on Medicare/Medicaid reimbursements (over 90% from Medicare), and both segments face material regulatory and seasonal/insurance cost risks that can swing margins and cash flow.

Executive Compensation Practices

Compensation at Chemed is likely tied to consolidated financial metrics (revenue, adjusted EBITDA, operating cash flow) and segment-level KPIs: for VITAS, days‑of‑care, Medicare rate realization, acuity mix and compliance/quality measures; for Roto‑Rooter, same‑store growth, margin, safety and cost control (including casualty insurance). The company has demonstrated substantial cash bonus outlays (e.g., VITAS’ Difference Maker Program paid >$39M) and uses stock‑based compensation (corporate expense trends show SBC variability), so pay mixes combine cash incentives and equity that mirror short‑term operating performance and longer‑term shareholder alignment. Given material regulatory exposure (Medicare caps, audits, FCA/OIG history) and frequent acquisitions, compensation plans commonly incorporate compliance and integration milestones and may include clawback or gating provisions tied to audit outcomes or restatements.

Insider Trading Considerations

Insider trading at Chemed may cluster around discrete, company‑specific events: quarterly earnings and Medicare‑cap/contra‑revenue disclosures (e.g., the recent $15M Medicare cap liability), acquisition announcements, large bonus payout dates, and share‑repurchase authorizations or leverage changes under the company’s credit facility. Regulatory scrutiny (OIG audits, historic FCA matters) and healthcare payment dependence increase the likelihood of formal blackout periods, the use of 10b5‑1 plans, and conservative trading policies for executives; look for sales following vesting/bonus payments or repurchase authorizations and opportunistic buys when management signals confidence in cash flow post‑integration. Day traders and researchers should monitor Section 16 filings for patterns tied to seasonal revenue swings (Roto‑Rooter weather sensitivity, VITAS Florida seasonality), Medicare rate announcements and material reserve or cap adjustments that materially affect short‑term compensation and insider liquidity needs.